STATEMENTS OF CONDENSED CONSOLIDATED CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net income (loss)	$ 1,219,233	$ (1,514,583)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income tax expense (benefit)	356,618	(473,557)
Depreciation and depletion	387,685	422,098
Impairments of long-lived assets and loss (gain) on sale/exchange of long-lived assets	27,074	213,727
(Income) loss from investments	(4,764)	20,785
(Gain) loss on debt extinguishment	(6,606)	6,923
Share-based compensation expense	11,276	7,470
Distribution of earnings from equity method investments	5,456	2,790
Amortization, accretion and other	3,888	10,389
(Gain) loss on derivatives	(824,852)	3,077,637
Net cash settlements received (paid) on derivatives	157,000	(885,539)
Net premiums (paid) received on derivative instruments	(94,916)	372
Changes in other assets and liabilities:
Accounts receivable	980,908	225,968
Accounts payable	(422,519)	52,867
Other current assets	(80,472)	(107,455)
Other items, net	(52,241)	(38,673)
Net cash provided by operating activities	1,662,768	1,021,219
Cash flows from investing activities:
Capital expenditures	(494,784)	(292,281)
Other investing activities	(3,542)	1,109
Net cash used in investing activities	(498,326)	(291,172)
Cash flows from financing activities:
Proceeds from credit facility borrowings	0	2,721,000
Repayment of credit facility borrowings	0	(2,695,000)
Repayment and retirement of debt	(211,429)	(570,174)
Discounts received (premiums paid) on debt extinguishment	7,981	(6,240)
Dividends paid	(54,070)	(47,063)
Repurchase and retirement of common stock	(201,029)	(216,491)
Distribution to noncontrolling interest, net of contributions	(85)	(341)
Other financing activities	(37,192)	(12,788)
Net cash used in financing activities	(495,824)	(827,097)
Net change in cash and cash equivalents	668,618	(97,050)
Cash and cash equivalents at beginning of period	1,458,644	113,963
Cash and cash equivalents at end of period	$ 2,127,262	$ 16,913